Psyence Biomedical Limited (PBM) Enterprise Value to EBITDA Ratio

Corporate emblem and logo of Psyence Biomedical Limited (PBM)

Psyence Biomedical Ltd. (PBM) business relies on the exploration of copper and gold deposits, planning to generate profit upon the completion of surveys. However, a transformation into the biotech sector and a shortage of funds create a risk of insolvency. Meanwhile, the company is implementing ESG standards for environmental protection. This chart of share price quotes with an EV/EBITDA metric at 0.00 clearly illustrates the asset's current state.

Psyence Biomedical Ltd - PBM Enterprise Value to EBITDA Ratio (period 11/23/2025 - 11/12/2026)

PBM (pacificbayminerals.com): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart Psyence Biomedical Limited|PBM - Analyst Median Target
- market capitalization details:
Market Valuation Psyence Bio|PBM - Total Enterprise Value
- business book valuation details:
Book Value per Share Psyence Biomedical|PBM - Company Net Assets|Market Capitalization to Book Value Ratio pacificbayminerals.com|PBM - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Psyence Biomedical Ltd.|PBM - Long-Term Liabilities to Capital|Short-Term Debt to Equity Psyence Biomedical|PBM - Company Aggregate Indebtedness|Debt to Book Capitalization Ratio Psyence Bio|PBM - Long-Term Debt Volume|Company Current Liabilities Psyence Biomedical|Quick Ratio pacificbayminerals.com
- financial results and valuation multiples details:
PBM - Company Net Income|Expected Profit Psyence Biomedical Ltd.|PBM - Price to Earnings Multiple|Forward P/E Multiple Psyence Biomedical Ltd.|PBM - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Psyence Bio|PBM - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Psyence Biomedical|PBM - Earnings per share for the trailing year|Quarterly EPS earnings growth pacificbayminerals.com|PBM - Earnings per share growth in current year|Earnings growth forecast for next year Psyence Biomedical Ltd.
Fundamental valuation:PBM (Psyence Biomedical Limited)
Original product of Psyence Biomedical

The development of Psyence Biomedical Ltd. (PBM) in the field of psychedelic therapy requires significant capital expenditures for clinical trials. The EV/EBITDA multiple compares the total enterprise value, including net debt, with operating profit before interest, taxes, depreciation, and amortization, thereby determining the payback period of the assets. Analyzing the current EV/EBITDA multiple allows investors to identify overvalued quotes and avoid freezing capital by purchasing the asset at the peak of market optimism.

Analysis of competing companies

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alkermes Inc. ALKS|Total Company Value to Operating Income Before Depreciation Ratio Avadel Corp (AVDL)|ATAI: Enterprise Value to EBITDA Ratio|Company Value to EBITDA ghres.com|MNMD: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio COMPASS Pathways PLC|LBRX (LB Pharma) - EV/EBITDA Multiple|DRUG: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Vanda Pharmaceuticals (VNDA)|CYBN - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alto Neuroscience ANRO|NRXP (NRx Pharmaceuticals Inc.) - Company Value to Operating Income Before Depreciation Ratio|CING - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Silo Pharma Inc. SILO|CPHI (chinapharmaholdings.com) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA clearmindmedicine.com (CMND)|SPRC (SciSparc) - EV/EBITDA Multiple|Company Value to EBITDA Seelos Therapeutics Inc. SEEL|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Virpax Pharmaceuticals (VRPX)|Karuna Pharma - Enterprise Value to Operating Income Before Depreciation